ALTIMMUNE, INC.
Moat Score — Altimmune, Inc.
Total Moat Score
5 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 2 / 5 | Altimmune holds patents covering pemvidutide's dual GLP-1/glucagon mechanism, but composition-of-matter protection in the crowded incretin space is narrower than the platform-level IP moats held by Novo Nordisk or Eli Lilly, and the molecule has no regulatory approval yet. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 0 / 5 | As a pre-commercial clinical-stage biotech with no manufacturing scale, Altimmune has no cost advantage; it will rely on contract manufacturers and would face a steep cost disadvantage versus Novo Nordisk and Eli Lilly's massive incretin production capacity if ever commercialized. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 1 / 5 | With no approved product, Altimmune has no current pricing power, and any future product would enter a market where payers already push back hard on GLP-1 pricing, limiting pricing power to differentiation-based premiums at best. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 0 / 5 | There is no network effect in a small-molecule/peptide pharmaceutical business model; value is driven entirely by clinical data and regulatory approval, not by user or usage scale effects. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 1 / 5 | Once patients are stabilized on an obesity or MASH therapy, some switching friction exists due to titration and tolerability adaptation, but with no approved product yet and multiple emerging competitors, Altimmune cannot currently claim any real switching-cost moat. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 1 / 5 | The obesity/metabolic disease market is enormous and can support multiple winners, so efficient-scale dynamics do not protect Altimmune; if anything, the market favors incumbents like Novo and Lilly who already possess manufacturing scale that a newcomer would need years to replicate. |